Compliance Rate
Compliance Rate
0%
Compliant submissions
0
Incompliant submissions
0
Total trials
0
My Organizations' Clinical Trials
Showing 3 of 3 entries
View as:
Phase: N/A
Priority: Normal
Start: 05/31/21
End: 05/31/24
Due: 05/31/25
Phase: N/A
Priority: Normal
Start: 04/15/22
End: 04/30/24
Due: 04/30/25
Phase: N/A
Priority: Normal
Start: 05/31/24
End: 12/31/26
Due: 12/31/27
| Title | NCT ID | Organization | User | Status | Start Date | End Date | Reporting Due Date | Last Checked | User Role | Org Created |
|---|---|---|---|---|---|---|---|---|---|---|
| A Study to Evaluate the Safety and Efficacy of ALMB-0168 in Patients With Osteosarcoma | NCT04886765 | AlaMab Therapeutics (Shanghai) Inc. | user2@example.com | None | 2021-05-31 | 2024-05-31 | 2025-05-31 | - | - | 2025-07-14 |
| Study to Evaluate the Safety and Pharmacokinetics of ALMB-0166 in Patients With Acute Spinal Cord Injury | NCT05524103 | AlaMab Therapeutics (Shanghai) Inc. | user2@example.com | None | 2022-04-15 | 2024-04-30 | 2025-04-30 | - | - | 2025-07-14 |
| A Study to Evaluate the Efficacy of ALMB-0168 in Solid Tumor Patients With Bone Metastatic Whose Prior Standard Treatment Have Failed | NCT06416358 | AlaMab Therapeutics (Shanghai) Inc. | user2@example.com | None | 2024-05-31 | 2026-12-31 | 2027-12-31 | - | - | 2025-07-14 |